Henderson Morley continues divestment discussions
This article was originally published in Scrip
Executive Summary
The UK biotechnology company Henderson Morley is in discussions for the sale of some of its ionic contraviral therapy (ICVT) portfolio as it continues plans to reshape itself into a purely vaccine-focused company by next year.